Nootropic Sleep Aid Agomelatine Melatonergic Antidepressant with Safe Pass

Nootropic Sleep Aid Agomelatine Melatonergic Antidepressant with Safe Pass

Abstracto

Nombre del producto:agomelatine

Sinónimos:norte-(2-(7-methoxynaphth-1-yl)ethyl)acetamida

No CAS.:138112-76-2

Peso molecular:243.30

Fórmula molecular:C15H17NO2

Punto de fusion:107-109 ° C

Punto de ebullición:478.8 °C at 760 mmHg

Apariencia:polvo blanco

Competitive price with high quality

Conforms to BP/USP/EP/FCC

What is Agomelatine?

Agomelatine (BAN, rINN; trade names Valdoxan, Melitor, Thymanax) is a melatonergic antidepressant developed by the pharmaceutical company Servier. Agomelatine is marketed for the treatment of major depressive disorder, primarily for its relatively favorable side effect profile: it avoids the weight gain, sexual dysfunction, and severe withdrawal associated with the most commonly used classes of antidepressants (SSRIs, SNRIs, tricyclics), while providing similar therapeutic benefit.

Due to its distinctive mechanism of action, agomelatine is also studied for its effects on sleep regulation. Studies report various improvements in general quality of sleep metrics, as well as specific therapeutic benefits in circadian rhythm disorders.

Medical Uses

Agomelatine is indicated for the treatment of major depressive episodes in adults.Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder. At the end of treatment, significant efficacy was demonstrated in six of the ten short-term double-blind placebo-controlled studies.Two were considered “failed” trials, as comparators of established efficacy failed to differentiate from placebo. Efficacy was also observed in more severely depressed patients in all positive placebo-controlled studies.The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study.

Results of the meta-analysis of three positive, randomized, doble ciego, placebo controlled studies in 357 patients treated with agomelatine and 360 patients treated with placebo show that agomelatine is effective in treating severe depression. Its antidepressant effect is greater for more severe depression. In patients with a greater baseline score (>30 on HAMD17 scale), the agomelatine-placebo difference was of 4.53 points.Controlled studies in humans have shown that agomelatine is at least as effective as the SSRI antidepressants paroxetine, sertraline, escitalopram, venlafaxine and fluoxetine in the treatment of major depression.